NDAINJECTIONINJECTABLE
Approved
Sep 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DECADRON-LA is a long-acting injectable corticosteroid containing dexamethasone acetate, approved by Merck & Co. in 1973. It is a small-molecule glucocorticoid used for systemic anti-inflammatory and immunosuppressive effects across multiple indications. The drug's mechanism relies on glucocorticoid receptor binding to reduce inflammation and immune activation.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); brand teams should expect resource rationalization and focus on legacy market defense.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect a mature, stable product with minimal growth trajectory. Career roles on DECADRON-LA typically involve market maintenance, managed decline strategy, and customer relationship management rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on DECADRON-LA at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.